

References

1. Shepard JW Jr, Buysse DJ, Chesson AL Jr, et al. History of the development of sleep medicine in the United States. *J Clin Sleep Med*. 2005;1(1):61-82.
2. Mignot E. History of narcolepsy at Stanford University. *Immunol Res*. 2014;58(2-3):315-339.
3. Yoss RE, Daly DD. Narcolepsy. *Med Clin North Am*. 1960;44:953-968.
4. Vogel GW. Studies in psychophysiology of dreams. III. The dream of narcolepsy. *Arch Gen Psychiatry*. 1960;3:421-428.
5. Carskadon MA, Dement WC. The multiple sleep latency test: what does it measure? *Sleep*. 1982;5 Suppl 2:S67-72.
6. Carskadon MA, Dement WC, Mitler MM, Roth T, Westbrook PR, Keenan S. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. *Sleep*. 1986;9(4):519-524.
7. Littner MR, Kushida C, Wise M, et al. Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. *Sleep*. 2005;28(1):113-121.
8. American Academy of Sleep Medicine. International Classification of Sleep Disorders, 3rd edition. Darien, IL: American Academy of Sleep Medicine; 2014.
9. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep*. 1991;14(6):540-545.
10. Wesnes KA. The CDR computerized assessment system for neuropsychological research. In: Hindmarch I, Stonier PD, eds. *Human Psychopharmacology: Measures and Methods*, Vol 1. Chichester: John Wiley & Sons; 1987:1-25.
11. Wesnes KA. The value of assessing cognitive function in drug development. *Dialogues Clin Neurosci*. 2000;2(3):183-202.
12. Simpson PM, Surmon DJ, Wesnes KA, Wilcock GK. The Cognitive Drug Research Computerized Assessment System for demented patients: a validation study. *Int J Geriatr Psychiatry*. 1991;6(2):95-102.
13. Ward T, Wesnes KA. The utility of computerized cognitive assessment in clinical drug development. *Curr Med Res Opin*. 2000;16(1):29-36.

14. Roth T, White D, Schmidt-Nowara W, et al. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. *Clin Ther*. 2006;28(5):689-706.
15. Harsh JR, Hayduk R, Rosenberg R, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. *Curr Med Res Opin*. 2006;22(4):761-774.
16. Schwartz JR, Khan A, McCall WV, Weintraub J, Tiller J. Tolerability and efficacy of armodafinil in naïve patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder, or narcolepsy: a 12-month, open-label, flexible-dose study with an extension period. *J Clin Sleep Med*. 2010;6(5):450-457.
17. Wesnes KA, Edgar C, Trull AK, Haque MS. The cognitive drug research computerised assessment system: validation of a system designed for repeated testing. *Curr Med Res Opin*. 2000;16(2):102-107.